摘要
目的观察奈达铂联合紫杉醇(TAX)治疗晚期非小细胞肺癌(NSCLC)的近期疗效、远期生存及毒副反应。方法采用前瞻性随机对照研究方法,以顺铂(DDP)联合TAX为对照,对60例ⅢB和Ⅳ期非小细胞肺癌初治患者进行随机分组。TN组30例,奈达铂30 mg/m2,第1～3天;TAX 175 mg/m2,第1天;每4周重复。TP组27例,DDP 30 mg/m2,第1～3天;TAX 175 mg/m2,第1天;每4周重复。结果TN组与TP组总有效率分别为43.3%和48.1%(P=0.716),疾病控制率分别为86.7%和88.8%(P=0.799)。TN组与TP组患者的中位生存期分别为14.3和13.0个月(P= 0.839),1年生存率分别为62.5%和59.1%,2年生存率分别为0和5.8%。TN组与TP组的中性粒细胞下降和血小板下降相近;TP组比TN组,贫血(38.5%和17.5%,P=0.001)、恶心呕吐(82.6%和35.6%,P=0.000)、乏力反应(35.9%和14.1%,P=0.000)及外周冲经毒性发生率(50.0%和21.9%,P=0.023)更高。结论奈达铂联合TAX是治疗NSCLC的有效方案,可取得与顺铂联合TAX相似的有效率和生存,在某些毒副反应方面显示出一定优势。
Objective To investigate the therapeutic effect, long term survival and side effect on NSCLC patients treated with nadaplatin combined with paclitaxol and cisplatin combined with paclitaxol. Methods NSCLC patients with stage Ⅲ s or Ⅳ were randomized into two groups in this prospective clinical study. TN group： nadaplatin 30 mg/m^2 dl-3, paclitaxol 175 mg/m^2 dl, repeated every 4 weeks. TP group： DDP 30 mg/m^2 dl-3, paclitaxol 175 mg/m^2 dl, repeated every 4 weeks. Results Sixty patients were enrolled and 57 were evaluable with 30 in TN group and 27 in TP group. The overall response rate were 43.3 % vs. 48.1% （ P = 0.716）, and the disease control rate were 86.7 % vs. 88.8% in TN and TP group （P=0.799）, respectively. The median survival time was 14.3 vs. 13.0 months, and the 1- and 2-year survival rate was 62.5% vs. 59.1%, 0% vs. 5.8% in TN and TP group （P =0. 839）, respectively. The rates of neutropenia and thrombocytopenia were similar in TN and TP groups whereas more patients in TP group than in TN group suffered from anemia （ 38.5% vs. 17.5%, P = 0. 001 ）, nausea and vomiting （82.6% vs. 35.6%, P=0.000）, fatigue （35.9% vs. 14.1%, P=0.000） and peripheral neurotoxicity （50.0% vs. 21.9%, calculated by case, P=0.023）. Conclusion Nadaplatin combined with paclitaxol is an effective treatment regimen for NSCLC patients. When compared with similar regimen with cisplatin, the response rate and survival were similar; however, nadaplatin regimen shows some superiority as regards some treatment side effect.
出处
《中华肿瘤杂志》
CAS
CSCD
北大核心
2007年第6期437-440,共4页
Chinese Journal of Oncology
关键词
奈达铂
非小细胞肺癌
紫杉醇
顺铂
Nadaplatin
Non-small cell lung cancer
Paclitaxol
Cisplatin
